Fevipiprant NEW
| Price | $29 | $43 | $88 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-01 |
Product Details
| Product Name: Fevipiprant | CAS No.: 872365-14-5 |
| Purity: 99.59% | Supply Ability: 10g |
| Release date: 2025/05/01 |
Product Introduction
Bioactivity
| Name | Fevipiprant |
| Description | Fevipiprant (NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist. |
| In vitro | CRTh2-mediated shape change in eosinophils was used to profile QAW039 in whole blood and represents a physiologically relevant environment. The comparable IC50 values for QAW039 in the whole blood and isolated shape-change assays are consistent with its lower plasma-protein binding and its relatively slow dissociation kinetics that drive its increased potency .QAW039 is highly potent in whole-blood systems, with the IC50 value obtained consistent with the affinity values calculated from radioligand experiments. In a further disease-relevant cellular context, the potency of QAW039 in the isolated Th2 cell cytokine inhibition assay is consistent with its CRTh2 receptor affinity, and, as with eosinophil assay readouts, this represents an improved potency compared with QAV680.[ |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (140.71 mM), Sonication is recommended. |
| Keywords | Th2 cells | QAW-039 | QAW 039 | ProstaglandinReceptor | Prostaglandin Receptor | orally active | NVP-QAW-039 | NVP-QAW 039 | Inhibitor | inhibit | IL-4 | Fevipiprant | CRTh2 | bronchial asthma | abdominal aortic aneurysm |
| Inhibitors Related | Angoroside C | Vincamine | Pranoprofen | Tranilast | Monomethyl fumarate | Rutin | Azathioprine | Ozagrel | Ethamsylate | Benzyl nicotinate | TUG-1375 | p-Hydroxycinnamic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Human Metabolite Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $2300.00/10gram |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-10-31 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-06-26 | ||
| $0.00/1g |
Wuhan Nutra Biotechnology Co.,Ltd
|
2021-05-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY